Antiviral therapy and resistance with hepatitis B virus infection

doi:10.3748/wjg.v13.i1.125

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 1

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2470)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-7) series, Tables (1-2) series.

Item

Count

PDF

296

HTML

1715

Figures (1-7)

277

Tables (1-2)

182

Sum=2470

Jan 7, 2007 (publication date) through Nov 18, 2024

Times Cited of This Article

Times Cited (65)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Jan 7, 2007; 13(1): 125-140
Published online Jan 7, 2007. doi: 10.3748/wjg.v13.i1.125

Full Size Figure Download Figure

Figure 2 Pre-emptive lamivudine is associated with lower frequency and lower severity of hepatitis during chemotherapy. Date given in percent (%). Adapted from Li YH, et al. Cancer 2006.

Citation: Tillmann HL. Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol 2007; 13(1): 125-140
URL: https://www.wjgnet.com/1007-9327/full/v13/i1/125.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i1.125